Literature DB >> 26055533

The early stages of tumor angiogenesis in human osteosarcoma: a nude mice xenotransplant model.

Francisco Giner1, José Antonio López-Guerrero, Isidro Machado, Zaida García-Casado, Amando Peydró-Olaya, Antonio Llombart-Bosch.   

Abstract

Osteosarcoma (Os) is the most common malignant bone tumor in childhood and not rare in adults. In recent years, much research has focused on the role of angiogenesis in tumor development, growth, invasion, and metastasis. The aims of this study were to characterize neovascularization established between the xenotransplanted Os and the host at histological, immunohistochemical, ultrastructural, and molecular level, and to evaluate if this model could be used in testing new anti-angiogenic drugs. Three xenotransplanted human Os were evaluated. Tumor pieces 3-4 mm in size were implanted subcutaneously on the back of athymic Balb-c nude mice (n = 14). The animals were killed at 24, 48, and 72 h and 7, 14, 21, and 28 days after implantation. Tumor samples were either fixed in 10 % formaldehyde and embedded in paraffin for histological analysis, or fixed with glutaraldehyde (2 %) for electron microscopy or retained non-fixed for molecular analysis (ELISA and qRT-PCR). Morphologically, intense neo-vasculogenesis within tumor parenchyma was present between the first and third week after transplantation. Immunohistochemistry demonstrated overexpression of VEGF and their receptors together with PDFGFRA 24-48 h after tumor implantation. Additionally, neoplastic cells co-expressed chemokines (CXCL9, CXCL10, and GRO) and their receptors. Molecular studies showed two expression profiles, distinguishing an early and a late phase in the angiogenic process. In Os, our model showed two stages of induced angiogenesis, with close association between histological and molecular events. This approximation could be of use for testing the effect of different anti-angiogenic agents.

Entities:  

Mesh:

Year:  2015        PMID: 26055533     DOI: 10.1007/s00428-015-1791-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia.

Authors:  Daisy W J van der Schaft; Femke Hillen; Patrick Pauwels; Dawn A Kirschmann; Karolien Castermans; Mirjam G A Oude Egbrink; Maxine G B Tran; Rafael Sciot; Esther Hauben; Pancras C W Hogendoorn; Olivier Delattre; Patrick H Maxwell; Mary J C Hendrix; Arjan W Griffioen
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 2.  The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review).

Authors:  Yu-Xin Liao; Cheng-Hao Zhou; Hui Zeng; Dong-Qing Zuo; Zhuo-Ying Wang; Fei Yin; Ying-Qing Hua; Zheng-Dong Cai
Journal:  Int J Mol Med       Date:  2013-10-11       Impact factor: 4.101

Review 3.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

4.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

Review 5.  Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

Authors:  Yvonne M H Versleijen-Jonkers; Myrella Vlenterie; Addy C M van de Luijtgaarden; Winette T A van der Graaf
Journal:  Crit Rev Oncol Hematol       Date:  2014-02-15       Impact factor: 6.312

6.  Prognostic relevance of increased angiogenesis in osteosarcoma.

Authors:  Michael Kreuter; Ralf Bieker; Stefan S Bielack; Tanja Auras; Horst Buerger; Georg Gosheger; Heribert Jurgens; Wolfgang E Berdel; Rolf M Mesters
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

7.  A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.

Authors:  Judy L Felgenhauer; Michael L Nieder; Mark D Krailo; Mark L Bernstein; David W Henry; David Malkin; Sylvain Baruchel; Paul J Chuba; Scott L Sailer; Ken Brown; Sarangarajan Ranganathan; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-10-12       Impact factor: 3.167

Review 8.  Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

Authors:  Herbert Hurwitz
Journal:  Clin Colorectal Cancer       Date:  2004-10       Impact factor: 4.481

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Correlation between the expression of vegf and survival in osteosarcoma.

Authors:  André Mathias Baptista; André Ferrari De França Camargo; Renée Zon Filippi; Cláudia Regina Gomes Cardim Mendes De Oliveira; Raymundo Soares De Azevedo Neto; Olavo Pires De Camargo
Journal:  Acta Ortop Bras       Date:  2014       Impact factor: 0.513

View more
  6 in total

1.  WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis.

Authors:  Chih-Yang Lin; Huey-En Tzeng; Te-Mao Li; Hsien-Te Chen; Yi Lee; Yi-Chen Yang; Shih-Wei Wang; Wei-Hung Yang; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2017-06-13

2.  WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma.

Authors:  Hsiao-Chi Tsai; Huey-En Tzeng; Chun-Yin Huang; Yuan-Li Huang; Chun-Hao Tsai; Shih-Wei Wang; Po-Chuan Wang; An-Chen Chang; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Cell Death Dis       Date:  2017-04-13       Impact factor: 8.469

3.  High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study.

Authors:  Francisco Giner; Isidro Machado; Jose Antonio Lopez-Guerrero; Empar Mayordomo-Aranda; Antonio Llombart-Bosch
Journal:  Ecancermedicalscience       Date:  2017-03-09

4.  Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition.

Authors:  Laura Pietrovito; Angela Leo; Valentina Gori; Matteo Lulli; Matteo Parri; Valentina Becherucci; Luisa Piccini; Franco Bambi; Maria Letizia Taddei; Paola Chiarugi
Journal:  Mol Oncol       Date:  2018-03-31       Impact factor: 6.603

5.  Anoikis‑resistant human osteosarcoma cells display significant angiogenesis by activating the Src kinase‑mediated MAPK pathway.

Authors:  Ziran Gao; Guo-Sheng Zhao; Yangfan Lv; Dongbin Peng; Xuefeng Tang; Hanxiang Song; Qiao-Nan Guo
Journal:  Oncol Rep       Date:  2018-10-29       Impact factor: 3.906

6.  Sphingosine-1-phosphate promotes PDGF-dependent endothelial progenitor cell angiogenesis in human chondrosarcoma cells.

Authors:  Chao-Qun Wang; Chih-Yang Lin; Yuan-Li Huang; Shih-Wei Wang; Yan Wang; Bi-Fei Huang; Yu-Wei Lai; Shun-Long Weng; Yi-Chin Fong; Chih-Hsin Tang; Zhong Lv
Journal:  Aging (Albany NY)       Date:  2019-12-06       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.